ATE218889T1 - Cytokine immunokonjugate - Google Patents

Cytokine immunokonjugate

Info

Publication number
ATE218889T1
ATE218889T1 AT92900745T AT92900745T ATE218889T1 AT E218889 T1 ATE218889 T1 AT E218889T1 AT 92900745 T AT92900745 T AT 92900745T AT 92900745 T AT92900745 T AT 92900745T AT E218889 T1 ATE218889 T1 AT E218889T1
Authority
AT
Austria
Prior art keywords
immunoconjugates
cytokine
disclosed
target cell
immunoglobulin
Prior art date
Application number
AT92900745T
Other languages
English (en)
Inventor
Stephen D Gillies
Original Assignee
Stephen D Gillies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stephen D Gillies filed Critical Stephen D Gillies
Application granted granted Critical
Publication of ATE218889T1 publication Critical patent/ATE218889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92900745T 1990-11-09 1991-11-07 Cytokine immunokonjugate ATE218889T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61209990A 1990-11-09 1990-11-09
PCT/US1991/008268 WO1992008495A1 (en) 1990-11-09 1991-11-07 Cytokine immunoconjugates

Publications (1)

Publication Number Publication Date
ATE218889T1 true ATE218889T1 (de) 2002-06-15

Family

ID=24451714

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900745T ATE218889T1 (de) 1990-11-09 1991-11-07 Cytokine immunokonjugate

Country Status (10)

Country Link
EP (2) EP0574395B1 (de)
JP (3) JPH09506761A (de)
AT (1) ATE218889T1 (de)
AU (1) AU660297B2 (de)
CA (1) CA2095836C (de)
DE (1) DE69133036T2 (de)
DK (1) DK0574395T3 (de)
ES (1) ES2178635T3 (de)
HK (2) HK1011286A1 (de)
WO (1) WO1992008495A1 (de)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
CA2090105A1 (en) * 1990-08-29 1992-03-01 Jean-Paul Soulillou Protein polyligands joined to a stable protein core
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
ATE207366T1 (de) * 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
ATE203274T1 (de) 1994-02-01 2001-08-15 Nasa Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
IT1271688B (it) * 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0706799B1 (de) * 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunokonjugate
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DE19716892C1 (de) * 1997-04-22 1998-09-03 Gsf Forschungszentrum Umwelt Expression von Immunglobulin-Zytokin-Fusionsproteinen in malignen B-Zellen
EP1037927B1 (de) * 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
EP1093457B8 (de) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
CA2328076C (en) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
CA2328081A1 (en) * 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
HU229520B1 (en) * 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1731531B1 (de) * 1999-08-09 2012-05-30 Merck Patent GmbH Mehrere Zytokin-Antikörper Komplexe
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2281843B1 (de) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Immunspezifisch bindende antikörper gegen BLyS
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
EP1256354A1 (de) * 2001-05-11 2002-11-13 Schering Corporation Verfahren zur Behandlung von Krebs
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2481747A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
EP1628992A4 (de) 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic Verfahren zur modulation der metastasierung sowie von metastasen herrührender verwandter ereignisse im skelett
EP1703893B1 (de) 2003-12-23 2012-04-11 Genentech, Inc. Neue anti-il 13-antikörper und verwendungen dafür
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006078776A2 (en) 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007008604A2 (en) 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
EP2238986A3 (de) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35-Antikörper und Verwendungen dafür
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
CN107929731A (zh) 2005-11-04 2018-04-20 健泰科生物技术公司 利用补体途径抑制剂治疗眼部疾病
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
BRPI0707276B1 (pt) 2006-01-27 2021-08-31 Biogen Ma Inc Polipeptídeo de fusão antagonista de receptor nogo
TW200813231A (en) 2006-04-13 2008-03-16 Novartis Vaccines & Diagnostic Methods of treating, diagnosing or detecting cancer
CN103709252B (zh) 2006-06-07 2016-12-07 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR064388A1 (es) 2006-12-18 2009-04-01 Genentech Inc Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
SG177954A1 (en) 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
SG177966A1 (en) 2007-01-09 2012-02-28 Biogen Idec Inc Sp35 antibodies and uses thereof
BRPI0806849A2 (pt) 2007-02-02 2015-06-23 Biogen Idec Inc Uso de semaforin 6a para a promoção de mielinização e diferenciação de oligodendrócitos
WO2008112988A2 (en) 2007-03-14 2008-09-18 Novartis Ag Apcdd1 inhibitors for treating, diagnosing or detecting cancer
EP2150562A1 (de) 2007-04-27 2010-02-10 Genetech, Inc. Starke, stabile und nicht immunsuppressive anti-cd4-antikörper
US8969024B2 (en) * 2007-08-28 2015-03-03 Abbvie Biotechnology Ltd Compositions and methods comprising binding proteins for adalimumab
NO2195023T3 (de) 2007-08-29 2018-08-04
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
DK2222707T3 (en) 2007-11-21 2016-04-11 Univ Oregon Health & Science Monoclonal anti-factor XI antibodies and method of use thereof
RU2528738C2 (ru) 2007-12-18 2014-09-20 Биоэллаенс К.В. Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
CN102065870B (zh) 2008-04-16 2014-11-19 比奥根艾迪克Ma公司 使用聚亚烷基二醇和过渡金属分离生物大分子的方法
WO2010005570A2 (en) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
JP5611210B2 (ja) 2008-09-07 2014-10-22 グリコネックス インコーポレイテッド 抗拡張ｉ型スフィンゴ糖脂質抗体、その誘導体および使用
EP2949666B1 (de) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
CA2770737C (en) 2009-08-13 2020-05-12 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US9034333B2 (en) 2010-08-27 2015-05-19 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
JP6097690B2 (ja) 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
EP2614080A1 (de) 2010-09-10 2013-07-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Phosphoryliertes twist1 und metastasen
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
EP2640738A1 (de) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antimykotische wirkstoffe
EP3628689A1 (de) 2010-12-17 2020-04-01 Neurimmune Holding AG Humane anti-sod1 antikörper
EP2686014A1 (de) 2011-03-16 2014-01-22 Sanofi Verwendung eines antikörperähnlichen proteins mit dualer v-region
EP2718457A4 (de) * 2011-06-06 2014-12-24 Immungene Inc Manipulierte ligandenfusionsmoleküle mit einem antikörper-tnfsf-element
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
EP2773665A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Antikörper und verfahren zur behandlung von krebs
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773664A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
EP2773667A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
TWI640537B (zh) 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
AU2013225812B2 (en) 2012-03-02 2017-11-30 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
KR102166083B1 (ko) 2012-03-28 2020-10-16 사노피 브라디키닌 b1 수용체 리간드에 대한 항체
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
SG11201407209YA (en) 2012-05-07 2014-12-30 Sanofi Sa Methods for preventing biofilm formation
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
KR101937733B1 (ko) 2012-05-24 2019-01-11 마운트게이트 그룹 리미티드 광견병 감염의 방지 및 치료에 관한 조성물 및 방법
EP2866831A1 (de) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences
EP2970396B1 (de) 2013-03-15 2022-02-23 Biological Mimetics, Inc. Immunogene zusammensetzungen des menschlichen rhinovirus (hrv)
US9920377B2 (en) 2013-03-15 2018-03-20 Sutter West Bay Hospitals FALZ for use as a target for therapies to treat cancer
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
EP3030902B1 (de) 2013-08-07 2019-09-25 Friedrich Miescher Institute for Biomedical Research Neues screening-verfahren zur behandlung von friedreich-ataxie
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
ES2770507T3 (es) 2013-08-13 2020-07-01 Sanofi Sa Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
SG10201803178UA (en) 2013-10-24 2018-05-30 Astrazeneca Ab Stable, aqueous antibody formulations
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015143271A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
EP3164129A1 (de) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
SG10201902850TA (en) 2014-09-30 2019-04-29 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
WO2016069999A2 (en) 2014-10-31 2016-05-06 Medimmune, Llc An improved manufacturing method
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
US10668150B2 (en) 2015-03-31 2020-06-02 Medimmune Limited IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
JP7020687B2 (ja) 2015-09-15 2022-02-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用
EP3865147A1 (de) 2015-10-02 2021-08-18 Silver Creek Pharmaceuticals, Inc. Bispezifische therapeutische proteine zur gewebereparatur
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
CA3010601A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
KR20220004226A (ko) 2016-03-22 2022-01-11 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
EP3618865A4 (de) 2017-05-05 2021-05-05 Vaccinex, Inc. Menschlicher anti-semaphorin-4d-antikörper
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US20210277118A1 (en) 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
MA56033A (fr) 2019-05-24 2022-04-06 Sanofi Sa Méthodes de traitement de la sclérodermie généralisée
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
KR20230146521A (ko) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 항체-피롤로벤조디아제핀 유도체 접합체
EP4277665A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3-antikörper-wirkstoff-konjugat
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IL91933A (en) * 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991013166A1 (en) * 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
WO1991014438A1 (en) * 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region

Also Published As

Publication number Publication date
HK1042925A1 (zh) 2002-08-30
EP0574395A1 (de) 1993-12-22
AU660297B2 (en) 1995-06-22
EP0574395B1 (de) 2002-06-12
ES2178635T3 (es) 2003-01-01
CA2095836C (en) 1999-04-06
AU9059691A (en) 1992-06-11
CA2095836A1 (en) 1992-05-10
HK1011286A1 (en) 1999-07-09
JP2006006339A (ja) 2006-01-12
JP3860398B2 (ja) 2006-12-20
DE69133036D1 (de) 2002-07-18
WO1992008495A1 (en) 1992-05-29
EP1149913A1 (de) 2001-10-31
DK0574395T3 (da) 2002-10-07
JPH09506761A (ja) 1997-07-08
JP2001095566A (ja) 2001-04-10
DE69133036T2 (de) 2003-02-06

Similar Documents

Publication Publication Date Title
ATE218889T1 (de) Cytokine immunokonjugate
Courtney et al. An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2
FI98217B (fi) Menetelmä nekroositekijän valmistamiseksi
RU2003100873A (ru) Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US5986061A (en) Phosphorylated fusion proteins
PT1380587E (pt) Oxazolo, thiazolo e selenazolo -(4, 5-c )- naftiridina- 4- amina e analogos destes compostos
DK1666591T3 (da) Cytokin der inducerer apoptose
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
EP0372707B1 (de) Modifizierte Proteine, modifizierte Interferone alpha- und beta-phosphorylierte Proteine, DNA-Sequenzen und Analoge und deren Verwendung
WO1995025170B1 (en) NOVEL MUTEINS OF IFN-$g(b)
FI864016A (fi) Med rekombinant-dna-teknik erhaollen kolonistimulerande faktor-1.
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
DE69535094D1 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
DK0866861T3 (da) Molekylær kloning og karakterisering af molekyler forbundet med relaxin og ligandinsulinfamilien
RU94045821A (ru) Трансгенные растения, проявляющие множественную устойчивость к вирусу, и способ их получения
WO2004093820A3 (en) Methods and compositions for solid tumor treatment
CA2360128A1 (en) Phosphyorylated fusion proteins and uses related thereto
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.
RU95101019A (ru) Способ получения фактора некроза опухоли, фактор некроза опухоли, днк, клетка, композиция

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0574395

Country of ref document: EP

EELA Cancelled due to lapse of time